TELA Bio Appoints Greg Firestone as Chief Commercial Officer MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Greg Firestone as the Company’s new Chief Commercial Officer. In this role, Mr. Firestone will oversee the Company’s commercial operations, including key product launches, sales team training, market development, as well as strategic initiatives to optimize market access and reimbursement strategy across...
Moody's Ratings (Moody's) affirmed JELD-WEN, Inc.'s (JELD-WEN) Ba3 corporate family rating (CFR), Ba3-PD probability of default rating (PDR), and the company's Ba2 senior secured term loan B rating. At the same time, Moody's upgraded JELD-WEN's senior unsecured notes ratings to B1 from B2. The SGL-2...
Last week began with hopes for a Senate markup of legislation that would provide, both, some short-term opportunities for reallocating spectrum for commercial wireless providers, and an extension of funding for the Affordable Connectivity Program (ACP). But the markup was pulled. In this update, we provide an analysis of what happened and what the implications are for the companies hoping for more funding or spectrum opportunities.
A director at Davita Inc sold 5,030 shares at 138.810USD and the significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Clene to Present at Upcoming May Conferences SALT LAKE CITY, May 14, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis and multiple sclerosis, today announced that it will participate in the following investor conferences in May. Mizuho Neuroscience Summit 2024Dates: May 20-21, 2024Location: ...
Petosemtamab erhielt von der FDA der USA die Breakthrough Therapy Designation • Petosemtamab erhielt die BTD für die Behandlung von bereits behandeltem HNSCC UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, May 14, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS), ein Unternehmen aus dem Bereich der klinischen Onkologie, das innovative multispezifische Antikörper in voller Länge (Biclonics® und Triclonics®) zur Krebsbehandlung entwickelt, gab heute bekannt, dass die US-Arzneimittelbehörde FDA Petosemtamab den Status eines Therapiedurchbruchs (Breakthrough Therapy Designation, BTD) zur Behan...
La FDA américaine a accordé le statut de thérapie innovante au pétosemtamab • Le pétosemtamab obtient le statut de thérapie innovante pour le traitement d’un carcinome épidermoïde de la tête et du cou (CETC) précédemment traité UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 14 mai 2024 (GLOBE NEWSWIRE) -- (Nasdaq : MRUS), une société d’oncologie au stade clinique qui développe des anticorps multispécifiques de pleine longueur innovants (Biclonics® and Triclonics®) pour le traitement du cancer, a annoncé aujourd’hui que la Food and Drug Administration (FDA) des États-Unis a ac...
Horizon Bancorp, Inc. Names John R. Stewart, CFA as Chief Financial Officer MICHIGAN CITY, Ind., May 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ GS: HBNC) – Horizon Bancorp, Inc. (“Horizon” or the “Company”) announced today that John R. Stewart, CFA has been named Horizon’s next Executive Vice President and Chief Financial Officer (CFO). Stewart will assume the responsibilities of CFO on May 20, 2024. Stewart has 22 years of financial services experience spanning banking, investment management and corporate finance at regional banks, global investment banks and institutional asset management fi...
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA Petosemtamab granted BTD for the treatment of previously treated HNSCC UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for petosemtamab for the treatment of patients with recurrent or metastatic head and neck squamous cel...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.